GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (STU:3XV) » Definitions » 3-Year FCF Growth Rate

Xvivo Perfusion AB (STU:3XV) 3-Year FCF Growth Rate : -5.10% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB 3-Year FCF Growth Rate?

Xvivo Perfusion AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was €0.00.

During the past 12 months, Xvivo Perfusion AB's average Free Cash Flow per Share Growth Rate was 138.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -5.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Xvivo Perfusion AB was 19.30% per year. The lowest was -79.60% per year. And the median was -45.90% per year.


Competitive Comparison of Xvivo Perfusion AB's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Xvivo Perfusion AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's 3-Year FCF Growth Rate falls into.



Xvivo Perfusion AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Xvivo Perfusion AB  (STU:3XV) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Xvivo Perfusion AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (STU:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (STU:3XV) Headlines

No Headlines